$TXMD
TherapeuticsMD, Inc. Stock $txmd

$txmd Overview Financials Valuation SEC Filings Company Website

2019 Q3 Form 10-Q Financial Statement

#000138713119005935 Filed on August 09, 2019

Income Statement

Concept	2019 Q3	2019 Q2	2019 Q1
Revenue	$23.72M	$6.079M	$3.950M
YoY Change	583.54%	61.55%	4.77%
Cost Of Revenue	$1.440M	$1.249M	$760.0K
YoY Change	105.71%	174.98%	20.63%
Gross Profit	$22.28M	$4.830M	$3.180M
YoY Change	704.15%	45.97%	1.27%
Gross Profit Margin	93.91%	79.45%	80.51%
Selling, General & Admin	$45.13M	$41.39M	$34.86M
YoY Change	48.7%	40.45%	67.92%
% of Gross Profit	202.6%	856.88%	1096.23%
Research & Development	$4.080M	$4.964M	$6.320M
YoY Change	-39.2%	-26.98%	-10.23%
% of Gross Profit	18.32%	102.78%	198.74%
Depreciation & Amortization	$140.0K	$66.56K	$110.0K
YoY Change	100.0%	63.22%	83.33%
% of Gross Profit	0.63%	1.38%	3.46%
Operating Expenses	$49.35M	$46.47M	$41.29M
YoY Change	32.91%	27.9%	48.21%
Operating Profit	-$27.08M	-$41.64M	-$38.11M
YoY Change	-21.2%	26.09%	54.17%
Interest Expense	-$5.600M	$4.029M	-$2.090M
YoY Change	173.17%	658.14%
% of Operating Profit
Other Income/Expense, Net	$700.0K	-$13.60M	$690.0K
YoY Change	-13.58%	6798.33%	122.58%
Pretax Income	-$31.97M	-$55.24M	-$39.51M
YoY Change	-10.22%	66.28%	61.93%
Income Tax
% Of Pretax Income
Net Earnings	-$31.97M	-$55.24M	-$39.51M
YoY Change	-10.23%	66.28%	61.9%
Net Earnings / Revenue	-134.77%	-908.65%	-1000.16%
Basic Earnings Per Share
Diluted Earnings Per Share	-$132.5K	-$229.0K	-$163.9K
COMMON SHARES
Basic Shares Outstanding	241.2B shares
Diluted Shares Outstanding

Balance Sheet

Concept	2019 Q3	2019 Q2	2019 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$155.3M	$182.8M	$122.9M
YoY Change	-18.26%	18.39%	14.54%
Cash & Equivalents
Short-Term Investments
Other Short-Term Assets	$10.60M	$7.800M	$9.800M
YoY Change	63.08%	50.0%	92.16%
Inventory	$10.50M	$7.494M	$5.000M
Prepaid Expenses
Receivables	$15.30M	$18.38M	$14.90M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$191.8M	$216.5M	$152.6M
YoY Change	-9.4%	29.54%	28.02%
LONG-TERM ASSETS
Property, Plant & Equipment	$12.80M	$1.432M	$700.0K
YoY Change	3100.0%	258.03%	75.0%
Goodwill
YoY Change
Intangibles		$4.688M
YoY Change
Long-Term Investments
YoY Change
Other Assets	$500.0K	$4.000M	$4.100M
YoY Change	-44.44%	344.44%	1950.0%
Total Long-Term Assets	$58.20M	$28.66M	$29.30M
YoY Change	131.87%	497.05%	671.05%
TOTAL ASSETS
Total Short-Term Assets	$191.8M	$216.5M	$152.6M
Total Long-Term Assets	$58.20M	$28.66M	$29.30M
Total Assets	$250.0M	$246.6M	$181.9M
YoY Change	5.57%	43.43%	47.89%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$24.10M	$19.50M	$25.40M
YoY Change	111.4%	71.05%	303.17%
Accrued Expenses	$33.70M	$14.00M	$12.50M
YoY Change	120.26%	79.49%	68.92%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$67.30M	$41.88M	$45.00M
YoY Change	129.69%	97.53%	186.62%
LONG-TERM LIABILITIES
Long-Term Debt	$194.4M	$194.1M	$73.50M
YoY Change	165.21%	165.52%
Other Long-Term Liabilities	$9.500M	$2.500M	$2.700M
YoY Change
Total Long-Term Liabilities	$203.9M	$194.1M	$76.20M
YoY Change	178.17%	165.52%
TOTAL LIABILITIES
Total Short-Term Liabilities	$67.30M	$41.88M	$45.00M
Total Long-Term Liabilities	$203.9M	$194.1M	$76.20M
Total Liabilities	$271.2M	$238.5M	$121.2M
YoY Change	164.59%	152.61%	671.97%
SHAREHOLDERS EQUITY
Retained Earnings		-$614.0M
YoY Change
Common Stock		$622.1M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$21.20M	$8.094M	$60.69M
YoY Change
Total Liabilities & Shareholders Equity	$250.0M	$246.6M	$181.9M
YoY Change	5.57%	43.43%	47.89%

Cashflow Statement

Concept	2019 Q3	2019 Q2	2019 Q1
OPERATING ACTIVITIES
Net Income	-$31.97M	-$55.24M	-$39.51M
YoY Change	-10.23%	66.28%	61.9%
Depreciation, Depletion And Amortization	$140.0K	$66.56K	$110.0K
YoY Change	100.0%	63.22%	83.33%
Cash From Operating Activities	-$26.22M	-$50.52M	-$38.16M
YoY Change	-23.04%	102.48%	94.2%
INVESTING ACTIVITIES
Capital Expenditures	-$1.300M	-$1.190M	-$670.0K
YoY Change	-93.61%	283.87%	294.12%
Acquisitions
YoY Change
Other Investing Activities	$0.00	-$20.00K	$0.00
YoY Change			-100.0%
Cash From Investing Activities	-$1.300M	-$1.210M	-$670.0K
YoY Change	-93.61%	290.32%	272.22%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	10.00K	111.7M	100.0K
YoY Change	-99.99%	54.48%	150.0%
NET CHANGE
Cash From Operating Activities	-26.22M	-50.52M	-38.16M
Cash From Investing Activities	-1.300M	-1.210M	-670.0K
Cash From Financing Activities	10.00K	111.7M	100.0K
Net Change In Cash	-27.51M	59.96M	-38.73M
YoY Change	-177.25%	27.47%	95.7%
FREE CASH FLOW
Cash From Operating Activities	-$26.22M	-$50.52M	-$38.16M
Capital Expenditures	-$1.300M	-$1.190M	-$670.0K
Free Cash Flow	-$24.92M	-$49.33M	-$37.49M
YoY Change	81.5%	100.2%	92.45%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	763247	USD
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	434677	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1092504	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	45720	USD
	dei	Entity Central Index Key EntityCentralIndexKey	0000025743
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2019
	dei	Document Type DocumentType	10-Q
	dei	Document Period End Date DocumentPeriodEndDate	2019-06-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-00100
	dei	Entity Registrant Name EntityRegistrantName	THERAPEUTICSMD, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	87-0233535
	dei	Entity Address Address Line1 EntityAddressAddressLine1	6800 Broken Sound Parkway NW
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Third Floor
	dei	Entity Address City Or Town EntityAddressCityOrTown	Boca Raton
	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	33487
	dei	City Area Code CityAreaCode	561
	dei	Local Phone Number LocalPhoneNumber	961-1900
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
	dei	Trading Symbol TradingSymbol	TXMD
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2019Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	241221840000	shares
CY2019Q2	us-gaap	Cash Cash	182846301	USD
CY2018Q4	us-gaap	Cash Cash	161613077	USD
CY2019Q2	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	764102	USD
CY2018Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	596602	USD
CY2019Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	18383012	USD
CY2018Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	11063821	USD
CY2019Q2	us-gaap	Inventory Net InventoryNet	7494440	USD
CY2018Q4	us-gaap	Inventory Net InventoryNet	3267670	USD
CY2019Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	7739048	USD
CY2018Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	10834693	USD
CY2019Q2	us-gaap	Assets Current AssetsCurrent	216462801	USD
CY2018Q4	us-gaap	Assets Current AssetsCurrent	186779261	USD
CY2019Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1432137	USD
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	472683	USD
CY2019Q2	txmd	License Rights LicenseRights	20000000	USD
CY2018Q4	txmd	License Rights LicenseRights	20000000	USD
CY2019Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	4688114	USD
CY2018Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	4092679	USD
CY2019Q2	us-gaap	Other Assets OtherAssets	3635227	USD
CY2018Q4	us-gaap	Other Assets OtherAssets	324855	USD
CY2019Q2	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	334866	USD
CY2018Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	314446	USD
CY2019Q2	us-gaap	Assets Noncurrent AssetsNoncurrent	28658207	USD
CY2018Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	24731980	USD
CY2019Q2	us-gaap	Assets Assets	246553145	USD
CY2018Q4	us-gaap	Assets Assets	211983924	USD
CY2019Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	19499238	USD
CY2018Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	22743841	USD
CY2019Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	22376617	USD
CY2018Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	18334948	USD
CY2019Q2	us-gaap	Liabilities Current LiabilitiesCurrent	41875855	USD
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	41078789	USD
CY2019Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	194095220	USD
CY2018Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	73381014	USD
CY2019Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2488101	USD
CY2019Q2	us-gaap	Liabilities Liabilities	238459176	USD
CY2018Q4	us-gaap	Liabilities Liabilities	114459803	USD
CY2018Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2019Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2018Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2019Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2019Q2	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2018Q4	us-gaap	Preferred Stock Value PreferredStockValue		USD
CY2018Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2019Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2018Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2019Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2019Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	241221840	shares
CY2019Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	241221840	shares
CY2018Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	240462439	shares
CY2018Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	240462439	shares
CY2019Q2	us-gaap	Common Stock Value CommonStockValue	241222	USD
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	240463	USD
CY2019Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	621871919	USD
CY2018Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	616559938	USD
CY2019Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-614019172	USD
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-519276280	USD
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	8093969	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	97524121	USD
CY2019Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	246553145	USD
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	211983924	USD
CY2019Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	6078865	USD
CY2018Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3763010	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	10025516	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7536402	USD
CY2019Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1248860	USD
CY2018Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	454161	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2011687	USD
	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1087784	USD
CY2019Q2	us-gaap	Gross Profit GrossProfit	4830005	USD
CY2018Q2	us-gaap	Gross Profit GrossProfit	3308849	USD
	us-gaap	Gross Profit GrossProfit	8013829	USD
	us-gaap	Gross Profit GrossProfit	6448618	USD
CY2019Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	41387451	USD
CY2018Q2	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	29466770	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	76251533	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	50224007	USD
CY2019Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4964368	USD
CY2018Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6798380	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	11282250	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	13837677	USD
CY2019Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	115059	USD
CY2018Q2	us-gaap	Depreciation And Amortization DepreciationAndAmortization	65603	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	221997	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	125224	USD
CY2019Q2	us-gaap	Operating Expenses OperatingExpenses	46466878	USD
CY2018Q2	us-gaap	Operating Expenses OperatingExpenses	36330753	USD
	us-gaap	Operating Expenses OperatingExpenses	87755780	USD
	us-gaap	Operating Expenses OperatingExpenses	64186908	USD
CY2019Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-41636873	USD
CY2018Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-33021904	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-79741951	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-57738290	USD
CY2019Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-10057632	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-10057632	USD
CY2019Q2	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	486597	USD
CY2018Q2	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	334238	USD
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	1175318	USD
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	648795	USD
CY2019Q2	us-gaap	Interest Expense InterestExpense	4028609	USD
CY2018Q2	us-gaap	Interest Expense InterestExpense	531382	USD
	us-gaap	Interest Expense InterestExpense	6118627	USD
	us-gaap	Interest Expense InterestExpense	531382	USD
CY2019Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-13599644	USD
CY2018Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-197144	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-15000941	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	117413	USD
CY2019Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-55236517	USD
CY2018Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-33219048	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-94742892	USD
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-57620877	USD
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-55236517	USD
CY2018Q2	us-gaap	Net Income Loss NetIncomeLoss	-33219048	USD
	us-gaap	Net Income Loss NetIncomeLoss	-94742892	USD
	us-gaap	Net Income Loss NetIncomeLoss	-57620877	USD
CY2019Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.23
CY2018Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.15
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.39
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.27
CY2019Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	241221840	shares
CY2018Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	216640186	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	241114532	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	216583067	shares
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	129908715	USD
CY2018Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1084939	USD
CY2018Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	44056	USD
CY2018Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1751358	USD
CY2018Q1	us-gaap	Net Income Loss NetIncomeLoss	-24401829	USD
CY2018Q1	us-gaap	Stockholders Equity StockholdersEquity	107302300	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	5224212	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	4128440	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	316880	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	30155	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	7486691	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	1335209	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	4226770	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	395219	USD
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-1710697	USD
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-2539394	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-3244603	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	7329560	USD
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	2801717	USD
	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	561615	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-88677723	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-44598893	USD
CY2018Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2377082	USD
CY2018Q2	us-gaap	Net Income Loss NetIncomeLoss	-33219048	USD
CY2018Q2	us-gaap	Stockholders Equity StockholdersEquity	77545273	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	97524121	USD
CY2019Q1	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	100107	USD
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2575369	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	-39506375	USD
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	60693222	USD
CY2019Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2637264	USD
CY2019Q2	us-gaap	Net Income Loss NetIncomeLoss	-55236517	USD
CY2019Q2	us-gaap	Stockholders Equity StockholdersEquity	8093969	USD
	us-gaap	Net Income Loss NetIncomeLoss	-94742892	USD
	us-gaap	Net Income Loss NetIncomeLoss	-57620877	USD
	us-gaap	Depreciation Depreciation	133049	USD
	us-gaap	Depreciation Depreciation	79201	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	88948	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	46023	USD
	us-gaap	Other Noncash Expense OtherNoncashExpense	78864	USD
	txmd	Noncash Operating Lease Expense NoncashOperatingLeaseExpense	443734	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	167500	USD
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	38024	USD
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-10057632	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	20420	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	11486	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1876171	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-491883	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	100107	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1128996	USD
	us-gaap	Repayments Of Other Long Term Debt RepaymentsOfOtherLongTermDebt	-81660719	USD
	us-gaap	Proceeds From Other Debt ProceedsFromOtherDebt	200000000	USD
	us-gaap	Proceeds From Other Debt ProceedsFromOtherDebt	75000000	USD
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	-6652270	USD
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	-3786918	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	111787118	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	72342078	USD
	us-gaap	Cash Period Increase Decrease CashPeriodIncreaseDecrease	21233224	USD
	us-gaap	Cash Period Increase Decrease CashPeriodIncreaseDecrease	27251302	USD
CY2018Q4	us-gaap	Cash Cash	161613077	USD
CY2017Q4	us-gaap	Cash Cash	127135628	USD
CY2019Q2	us-gaap	Cash Cash	182846301	USD
CY2018Q2	us-gaap	Cash Cash	154386930	USD
	us-gaap	Interest Paid Net InterestPaidNet	6989570	USD
	us-gaap	Nature Of Operations NatureOfOperations	<div style="display: inline; text-decoration: underline; font: bold 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1 – THE COMPANY</b></span></div> <div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"> </div> <div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">TherapeuticsMD, Inc., a Nevada corporation, or TherapeuticsMD or the Company, has three wholly owned subsidiaries, vitaMedMD, LLC, a Delaware limited liability company, or VitaMed; BocaGreenMD, Inc., a Nevada corporation, or BocaGreen; and VitaCare Prescription Services, Inc., a Florida corporation, or VitaCare. Unless the context otherwise requires, TherapeuticsMD, VitaMed, BocaGreen, and VitaCare collectively are sometimes referred to as “our company,” “we,” “our,” or “us.”</div> <div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"> </div> <div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"> <div style="display:inline;text-decoration:underline">Nature of Business</div></div> <div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0"> </div> <div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">We are a women’s healthcare company focused on creating and commercializing innovative products to support the lifespan of women and championing awareness of women’s healthcare issues, specifically, for pregnancy prevention, pregnancy, childbirth, nursing, pre-menopause, and menopause. At TherapeuticsMD, we combine entrepreneurial spirit, clinical expertise, and business leadership to develop and commercialize health solutions that enable new standards of care for women. Our solutions range from advanced hormone therapy pharmaceutical products to patient-controlled, long-acting contraceptive. We also manufacture and distribute branded and generic prescription prenatal vitamins under the vitaMedMD<sup>®</sup> and BocaGreenMD<sup>®</sup> brands.</div> <div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"> </div> <div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">With our SYMBODA™ technology, we are developing and commercializing advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes. Our track record of commercialization allows us to efficiently leverage and grow our marketing and sales organization to commercialize our recently approved products.</div> <div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"> </div> <div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify">During 2018 , U.S. Food and Drug Administration, or FDA, approval of our drugs has transitioned our company from predominately focused on conducting research and development to one focused on commercializing our drugs. In July 2018, we launched our FDA-approved product, IMVEXXY® (estradiol vaginal inserts) for the treatment of moderate-to-severe dyspareunia (vaginal pain associated with sexual activity), a symptom of vulvar and vaginal atrophy, or VVA, due to menopause. In April 2019, we launched BIJUVA®, our hormone therapy combination of bio-identical 17 ß-estradiol and bio-identical progesterone in a single, oral softgel capsule, for the treatment of moderate-to-severe vasomotor symptoms, or VMS, due to menopause in women with a uterus. We are also focused on commercialization activities necessary for launch of ANNOVERA™ (segesterone acetate/ethinyl estradiol vaginal system), the first and only patient-controlled, procedure-free, reversible prescription contraceptive that can prevent unintended pregnancy for up to a full year, which was approved by the FDA on August 10, 2018. On July 30, 2018, we entered into a license and supply agreement with Knight Therapeutics Inc., or Knight, pursuant to which we granted Knight an exclusive license to commercialize IMVEXXY and BIJUVA in Canada and Israel. In addition, on July 30, 2018, we entered into an exclusive license agreement, or the Council License Agreement, with the Population Council, Inc., or the Population Council, to commercialize ANNOVERA in the U.S. On June 6, 2019, we entered into an exclusive license and supply agreement with Theramex HQ UK Limited, or Theramex, a leading, global specialty pharmaceutical company dedicated to women’s health, to commercialize BIJUVA and IMVEXXY outside of the U.S., excluding Canada and Israel.</div>
CY2019Q2	txmd	Number Of Subsidiares NumberOfSubsidiares	3	pure
CY2019Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3800000	USD
CY2019Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	4100000	USD
	txmd	Shelf Life Of Prescription Products ShelfLifeOfPrescriptionProducts	P24M
	txmd	Enrolled Patients EnrolledPatients	35	USD
CY2019Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	6078865	USD
CY2018Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	3763010	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	10025516	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	7536402	USD
CY2019Q2	us-gaap	Deferred Finance Costs Current Net DeferredFinanceCostsCurrentNet	550757	USD
CY2019Q2	us-gaap	Inventory Finished Goods InventoryFinishedGoods	4382969	USD
CY2018Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	2908958	USD
CY2019Q2	us-gaap	Inventory Work In Process InventoryWorkInProcess	439993	USD
CY2018Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	339312	USD
CY2019Q2	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	2671478	USD
CY2018Q4	us-gaap	Inventory Raw Materials And Supplies InventoryRawMaterialsAndSupplies	19400	USD
CY2019Q2	us-gaap	Inventory Net InventoryNet	7494440	USD
CY2018Q4	us-gaap	Inventory Net InventoryNet	3267670	USD
CY2019Q2	txmd	Prepaid Sales And Marketing Costs Current PrepaidSalesAndMarketingCostsCurrent	2568100	USD
CY2018Q4	txmd	Prepaid Sales And Marketing Costs Current PrepaidSalesAndMarketingCostsCurrent	5148789	USD
CY2018Q4	us-gaap	Deferred Finance Costs Current Net DeferredFinanceCostsCurrentNet	1898074	USD
CY2019Q2	us-gaap	Prepaid Insurance PrepaidInsurance	686891	USD
CY2018Q4	us-gaap	Prepaid Insurance PrepaidInsurance	790465	USD
CY2019Q2	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	3933300	USD
CY2018Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	2997365	USD
CY2019Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	7739048	USD
CY2018Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	10834693	USD
CY2019Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2118817	USD
CY2018Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1026313	USD
CY2019Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	686680	USD
CY2018Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	553630	USD
CY2019Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1432137	USD
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	472683	USD
CY2019Q2	us-gaap	Depreciation Depreciation	66556	USD
CY2018Q2	us-gaap	Depreciation Depreciation	40777	USD
	us-gaap	Depreciation Depreciation	133049	USD
	us-gaap	Depreciation Depreciation	79201	USD
CY2019Q2	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	5058452	USD
CY2019Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	370338	USD
CY2019Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	4688114	USD
CY2018Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	4477391	USD
CY2018Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	384712	USD
CY2018Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	4092679	USD
	txmd	Intangible Written Offf IntangibleWrittenOfff	78864	USD
CY2019Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	48503	USD
CY2018Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	24826	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	88948	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	46023	USD
CY2019Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	35240	USD
CY2018Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	375573	USD
CY2019Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	22376617	USD
CY2019Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	96008	USD
CY2019Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	196017	USD
CY2019Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	196017	USD
CY2019Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	196017	USD
CY2019Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	196017	USD
CY2019Q2	txmd	Cash Upfront Payment Due CashUpfrontPaymentDue	14000000	EUR
CY2019Q2	txmd	Regulatory Milestone Payment Due RegulatoryMilestonePaymentDue	2000000	EUR
CY2019Q2	txmd	Sales Milestone Payments SalesMilestonePayments	27500000	EUR
CY2019Q2	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	5115082	USD
CY2018Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	6854002	USD
CY2019Q2	txmd	Sales Discounts Returns And Allowances Goods1 SalesDiscountsReturnsAndAllowancesGoods1	6340450	USD
CY2018Q4	txmd	Sales Discounts Returns And Allowances Goods1 SalesDiscountsReturnsAndAllowancesGoods1	5294120	USD
CY2019Q2	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	2107696	USD
CY2018Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	2288028	USD
CY2019Q2	us-gaap	Accrued Vacation Current AccruedVacationCurrent	1492131	USD
CY2018Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	1178110	USD
CY2019Q2	txmd	Allowance For Wholesale Distributor Fees Current AllowanceForWholesaleDistributorFeesCurrent	2077444	USD
CY2018Q4	txmd	Allowance For Wholesale Distributor Fees Current AllowanceForWholesaleDistributorFeesCurrent	792891	USD
CY2019Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	367898	USD
CY2018Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	385824	USD
CY2019Q2	txmd	Accrued Research And Development AccruedResearchAndDevelopment	1402600	USD
CY2018Q4	txmd	Accrued Research And Development AccruedResearchAndDevelopment	388675	USD
CY2019Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1187029	USD
CY2018Q4	us-gaap	Accrued Rent Current AccruedRentCurrent	365155	USD
CY2019Q2	txmd	Accrued Rebates AccruedRebates	2251047	USD
CY2018Q4	txmd	Accrued Rebates AccruedRebates	412570	USD
CY2018Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	18334948	USD
CY2019Q2	txmd	Repayment Of Debt With New Credit Facility RepaymentOfDebtWithNewCreditFacility	81661000	USD
CY2019Q2	txmd	Prepayment Fee PrepaymentFee	0.04	pure
CY2019Q2	txmd	Repayment Fee Percent RepaymentFeePercent	0.04	pure
CY2019Q2	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-10057632	USD
CY2019Q2	txmd	Deferred Financing Fees DeferredFinancingFees	6652270	USD
	txmd	Amortization Of Deferred Financing Fees AmortizationOfDeferredFinancingFees	196734	USD
CY2019Q2	txmd	Amortization Of Deferred Financing Fees AmortizationOfDeferredFinancingFees	196734	USD
	us-gaap	Interest Expense Borrowings InterestExpenseBorrowings	3985000	USD
CY2019Q2	us-gaap	Interest Expense Borrowings InterestExpenseBorrowings	3985000	USD
CY2019Q2	us-gaap	Debt Instrument Interest Rate Effective Percentage DebtInstrumentInterestRateEffectivePercentage	0.11	pure
CY2019Q2	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	5904780	USD
CY2018Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	1618986	USD
CY2019Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	194095220	USD
CY2018Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	73381014	USD
CY2019Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	24945040	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	24945040	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	28218470	shares
CY2018Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	28218470	shares
CY2019Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2019Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	350000000	shares
CY2019Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	241221840	shares
CY2019Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	241221840	shares
	txmd	Number Of Stock Options Exercised NumberOfStockOptionsExercised	276383	shares
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	100107	USD
	txmd	Number Of Stock Options Exercised In Cashless Exercise NumberOfStockOptionsExercisedInCashlessExercise	12097	shares
	txmd	Number Of Common Stock Issued During Period For Stock Options Exercised In Cashless Exercise Shares NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares	11834	shares
	txmd	Number Of Stock Options Exercised In Cashless Exercise NumberOfStockOptionsExercisedInCashlessExercise	10000	shares
	txmd	Number Of Common Stock Issued During Period For Stock Options Exercised In Cashless Exercise Shares NumberOfCommonStockIssuedDuringPeriodForStockOptionsExercisedInCashlessExerciseShares	9841	shares
CY2019Q2	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	1832571	USD
	txmd	Warrants And Rights Weighted Average Contractual Remaining Life WarrantsAndRightsWeightedAverageContractualRemainingLife	P2Y6M
CY2019Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	139000	USD
CY2019Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	16812383	shares
CY2019Q2	txmd	Plan Awards Number Of New Shares PlanAwardsNumberOfNewShares	14362500	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.57
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.15
CY2019Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2230829	USD
CY2018Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2212241	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4374069	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3872125	USD
CY2019Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	11606000	USD
CY2019Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	172651	USD
CY2019Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	176968	USD
CY2019Q2	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	1228504	USD
CY2019Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	4602153	USD
CY2019Q2	txmd	Lessee Operating Lease Liability Imputed Interest Amount LesseeOperatingLeaseLiabilityImputedInterestAmount	927023	USD
CY2019Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	3675130	USD
CY2019Q2	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	13300000	USD
CY2019Q2	txmd	Operating Leases Future Minimum Variable Payments Due Future Minimum OperatingLeasesFutureMinimumVariablePaymentsDueFutureMinimum	6400000	USD
CY2019Q2	us-gaap	Operating Lease Expense OperatingLeaseExpense	295000	USD
CY2019Q2	us-gaap	Related Party Transaction Purchases From Related Party RelatedPartyTransactionPurchasesFromRelatedParty	974000	USD
CY2018Q2	us-gaap	Related Party Transaction Purchases From Related Party RelatedPartyTransactionPurchasesFromRelatedParty	1266000	USD
CY2019Q2	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	243000	USD
CY2018Q4	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	88000	USD
	us-gaap	Concentration Risk Percentage1 ConcentrationRiskPercentage1	0.60	pure
	us-gaap	Concentration Risk Percentage1 ConcentrationRiskPercentage1	0.71	pure
CY2019Q2	txmd	Reimbursement From Landlord Tenant Improvements ReimbursementFromLandlordTenantImprovements	1800000	USD
	txmd	Schedule Of Supplemental Lease Information And Cash Flow Information ScheduleOfSupplementalLeaseInformationAndCashFlowInformation	<div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:center"> </div> <table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:60%;font:10pt Times New Roman, Times, Serif;margin:auto"> <tbody> <tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif"> <td style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif"> <div style="display:inline;font-weight:bold">Supplemental lease information as of June 30, 2019</div></td> <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"> <div style="display:inline;font-weight:bold"> </div></td> <td colspan="2" style="font-family:Times New Roman, Times, Serif"> <div style="display:inline;font-weight:bold"> </div></td> <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"> <div style="display:inline;font-weight:bold"> </div></td></tr> <tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif"> <td style="width:44%;text-align:left;font-family:Times New Roman, Times, Serif">Right-of-use asset (included in Other assets)</td> <td style="width:2%;font-family:Times New Roman, Times, Serif"> </td> <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">$</td> <td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif">3,316,436</td> <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif"> <td style="text-align:left;font-family:Times New Roman, Times, Serif">Short-term operating lease liability (included in Other current liabilities)</td> <td style="font-family:Times New Roman, Times, Serif"> </td> <td style="text-align:left;font-family:Times New Roman, Times, Serif">$</td> <td style="text-align:right;font-family:Times New Roman, Times, Serif">1,187,029</td> <td style="text-align:left;font-family:Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif"> <td style="text-align:left;font-family:Times New Roman, Times, Serif">Long-term operating lease liability</td> <td style="font-family:Times New Roman, Times, Serif"> </td> <td style="text-align:left;font-family:Times New Roman, Times, Serif">$</td> <td style="text-align:right;font-family:Times New Roman, Times, Serif">2,488,101</td> <td style="text-align:left;font-family:Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif"> <td style="font-family:Times New Roman, Times, Serif">Weighted average remaining term</td> <td style="font-family:Times New Roman, Times, Serif"> </td> <td style="text-align:left;font-family:Times New Roman, Times, Serif"> </td> <td style="text-align:right;font-family:Times New Roman, Times, Serif"> <div style="display:inline;font-family:Times New Roman, Times, Serif;font-size:10pt">5Years</div></td> <td style="text-align:left;font-family:Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif"> <td style="font-family:Times New Roman, Times, Serif">Weighted average discount rate</td> <td style="font-family:Times New Roman, Times, Serif"> </td> <td style="text-align:left;font-family:Times New Roman, Times, Serif"> </td> <td style="text-align:right;font-family:Times New Roman, Times, Serif">8.25</td> <td style="text-align:left;font-family:Times New Roman, Times, Serif">%</td></tr></tbody> </table> <div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"> </div> <table cellpadding="0" cellspacing="0" style="border-collapse:collapse;width:60%;font:10pt Times New Roman, Times, Serif;margin:auto"> <tbody> <tr style="vertical-align:bottom;font-family:Times New Roman, Times, Serif"> <td style="text-align:center;border-bottom:Black 1pt solid;font-family:Times New Roman, Times, Serif"> <div style="display:inline;font-weight:bold">Supplemental cash flow information<br/>for the six months ended June 30, 2019</div></td> <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"> <div style="display:inline;font-weight:bold"> </div></td> <td colspan="2" style="font-family:Times New Roman, Times, Serif"> <div style="display:inline;font-weight:bold"> </div></td> <td style="padding-bottom:1pt;font-family:Times New Roman, Times, Serif"> <div style="display:inline;font-weight:bold"> </div></td></tr> <tr style="vertical-align:bottom;background-color:rgb(204,238,255);font-family:Times New Roman, Times, Serif"> <td style="width:44%;text-align:left;font-family:Times New Roman, Times, Serif">Cash paid for amounts included in the measurement of lease liabilities for operating lease</td> <td style="width:2%;font-family:Times New Roman, Times, Serif"> </td> <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif">$</td> <td style="width:12%;text-align:right;font-family:Times New Roman, Times, Serif">564,092</td> <td style="width:1%;text-align:left;font-family:Times New Roman, Times, Serif"> </td></tr> <tr style="vertical-align:bottom;background-color:White;font-family:Times New Roman, Times, Serif"> <td style="text-align:left;font-family:Times New Roman, Times, Serif">Right-of-use assets obtained in exchange for lease obligation</td> <td style="font-family:Times New Roman, Times, Serif"> </td> <td style="text-align:left;font-family:Times New Roman, Times, Serif">$</td> <td style="text-align:right;font-family:Times New Roman, Times, Serif">3,760,171</td> <td style="text-align:left;font-family:Times New Roman, Times, Serif"> </td></tr></tbody> </table> <div style="font:10pt Times New Roman, Times, Serif;margin:0pt 0;text-align:justify"> </div>
CY2019Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3316436	USD
CY2019Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1187029	USD
CY2019Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2488101	USD
CY2019Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y
CY2019Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0825	pure
CY2019Q2	us-gaap	Operating Lease Payments OperatingLeasePayments	564092	USD
CY2019Q2	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	3760171	USD
CY2019Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	595649	USD
CY2019Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1292914	USD
CY2019Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1135467	USD
	us-gaap	Operating Lease Expense OperatingLeaseExpense	590000	USD
CY2019Q2	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	257000	USD
	us-gaap	Lease And Rental Expense LeaseAndRentalExpense	515000	USD

Files In Submission

Name	View Source	Status
0001387131-19-005935-index-headers.html	Edgar Link	pending
0001387131-19-005935-index.html	Edgar Link	pending
0001387131-19-005935.txt	Edgar Link	pending
0001387131-19-005935-xbrl.zip	Edgar Link	pending
ex10-1.htm	Edgar Link	pending
ex10-2.htm	Edgar Link	pending
ex10-3.htm	Edgar Link	pending
ex102001.jpg	Edgar Link	pending
ex102002.jpg	Edgar Link	pending
ex102003.jpg	Edgar Link	pending
ex102004.jpg	Edgar Link	pending
ex102005.jpg	Edgar Link	pending
ex102006.jpg	Edgar Link	pending
ex102007.jpg	Edgar Link	pending
ex102008.jpg	Edgar Link	pending
ex102009.jpg	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
txmd-10q_063019.htm	Edgar Link	pending
txmd-10q_063019_htm.xml	Edgar Link	completed
txmd-20190630.xsd	Edgar Link	pending
txmd-20190630_cal.xml	Edgar Link	unprocessable
txmd-20190630_def.xml	Edgar Link	unprocessable
txmd-20190630_lab.xml	Edgar Link	unprocessable
txmd-20190630_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TXMD
TherapeuticsMD, Inc. Stock $txmd

2019 Q3 Form 10-Q Financial Statement

#000138713119005935 Filed on August 09, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TXMD TherapeuticsMD, Inc. Stock $txmd

2019 Q3 Form 10-Q Financial Statement

#000138713119005935 Filed on August 09, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TXMD
TherapeuticsMD, Inc. Stock $txmd